Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05741489 · ClinicalTrials.gov registry record · NA
Continuous Glucose Monitoring in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes
A NA study of End-Stage Kidney Disease, sponsored by Emory University.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 4
- Study locations
NCT05741489: Completed NA study of End-Stage Kidney Disease, sponsored by Emory University.
NCT05741489 is a NA study of End-Stage Kidney Disease that has completed, run by Emory University. The registered enrollment target is 40 participants, below the 464-participant average among 20 other End-Stage Kidney Disease trials with a reported enrollment target (91% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05741489, a NA study of End-Stage Kidney Disease, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
Twenty participants with end stage kidney disease (ESKD) and burnt-out diabetes, and 20 non-diabetic participants with ESKD will wear a continuous glucose monitoring (CGM) device for 10 days to see if the use of CGM is a better tool to assess glycemic control than glycosylated hemoglobin (HbA1c) in patients with ESKD on dialysis.
Primary Outcome
Glycemic control is measured as the percentage of time that blood glucose levels are in the range of 70 and 180 mg/dL, as measured by CGM.
Conditions Studied
Interventions
- DEVICE Continuous glucose monitoring (CGM)
Study Locations (4)
Georgia
- Grady Memorial Hospital - Atlanta
- Emory Dialysis at Northside - Atlanta
- Emory Dialysis at Greenbriar - Atlanta
- Emory Dialysis at Candler - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-08-10 |
| Est. Completion | 2023-03-09 |
| Phase | NA |
What the finished NCT05741489 record still lists
NCT05741489 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 464-participant average among 20 other End-Stage Kidney Disease trials with a reported enrollment target (91% lower).
The record links to 1 condition, with End-Stage Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Continuous glucose monitoring (CGM) is the first listed.
NCT05741489 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT05741489 about?
NCT05741489 is a clinical study titled "Continuous Glucose Monitoring in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes". Twenty participants with end stage kidney disease (ESKD) and burnt-out diabetes, and 20 non-diabetic participants with ESKD will wear a continuous glucose monitoring (CGM) device for 10 days to see if the use of CGM is a better tool to assess glycemic control than glycosylated hemoglobin (HbA1c) in ...
What is the current status of trial NCT05741489?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2022-08-10. Estimated completion is 2023-03-09.
What conditions does trial NCT05741489 study?
This clinical trial studies the following conditions: End-Stage Kidney Disease.
What interventions are being tested in trial NCT05741489?
The interventions under investigation include: Continuous glucose monitoring (CGM) (DEVICE).
Who is sponsoring clinical trial NCT05741489?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05741489 being conducted?
This trial has 4 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End-Stage Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05741489's enrollment target sits among peer trials
40 15th of 20 higher than 6 of 20 other End-Stage Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End-Stage Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Incremental Hemodialysis: The TwoPlus Trial
RECRUITING · NA
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
-
Symptom Monitoring in Hemodialysis
RECRUITING · NA
-
Moda-flx Hemodialysis System™ Under Professional Care Settings by Trained Individuals and At Home by Participants
RECRUITING · NA
-
Pain Reduction Using NEurostimulation Study
RECRUITING · NA
-
Staged Kidney Transplantation During Combined Heart/Kidney Transplantation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI